Volume | 1,069,449 |
|
|||||
News | (1) | ||||||
Day High | 97.44 | Low High |
|||||
Day Low | 94.98 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Natera Inc | NTRA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
95.88 | 94.98 | 97.44 | 96.98 | 93.72 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
19,321 | 1,069,449 | US$ 96.22 | US$ 102,897,485 | - | 36.90 - 98.82 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
16:42:55 | 3 | US$ 95.69 | USD |
Natera Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
11.71B | 120.76M | - | 1.08B | -434.8M | -3.60 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Natera News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NTRA Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 92.00 | 97.44 | 90.8822 | 93.55 | 876,350 | 4.98 | 5.41% |
1 Month | 94.93 | 98.82 | 83.13 | 92.14 | 1,119,882 | 2.05 | 2.16% |
3 Months | 69.35 | 98.82 | 67.33 | 87.26 | 1,401,490 | 27.63 | 39.84% |
6 Months | 41.05 | 98.82 | 40.61 | 72.13 | 1,429,961 | 55.93 | 136.25% |
1 Year | 50.60 | 98.82 | 36.90 | 61.92 | 1,265,627 | 46.38 | 91.66% |
3 Years | 111.42 | 129.09 | 26.10 | 59.45 | 1,335,330 | -14.44 | -12.96% |
5 Years | 19.62 | 129.09 | 16.87 | 58.24 | 1,109,284 | 77.36 | 394.29% |
Natera Description
Natera Inc is operative in the healthcare field in the United States. Its core business is to offer invasive and other means of diagnosing the genetic features of a fetus. Natera's array of diagnostic services includes Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, Anora Products of Conception (POC) test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing (PAT), to determine paternity by studying the fragments of fetal deoxyribonucleic acid (DNA) in a pregnant mother's blood and a blood sample from the alleged father. The Company acquires its revenue by billing an insurance carrier, a clinic, or a patient for the test upon delivery of the test result. |